arrow_back Trending Legislation
Share share

Increased Transparency in Generic Drug Approvals

New rules aim to increase transparency in the generic drug approval process. Pharmaceutical companies will find it easier to verify if their generic drugs are identical to original ones, potentially speeding up access to more affordable alternatives. Citizens may benefit from quicker access to generic medications.
Key points
Generic drug manufacturers can request information on original drug composition to ensure their versions are identical.
If a generic differs from the original, the agency must disclose which ingredients and quantities are different.
The agency cannot reverse its decision on drug identity unless the original drug was withdrawn for safety reasons or an error was identified.
Clear guidelines on how the agency will assess generic drug identity are to be issued within one year.
article Official text account_balance Process page notifications_active Track this Bill
gavel
Status:
Expired
Record your position for audit.
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.
Additional Information
To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
Print number: HR 3839
Sponsor: Rep. Dunn, Neal P. [R-FL-2]
Process start date: 2023-06-06
System Note: Lustra is free, publicly auditable civic infrastructure, with full source code available on GitHub. You are reading sterilized legislative data, processed by our radical neutrality engine to strip political spin and retain factual mechanics. We process only official government data. Original documents remain the authoritative source, always verify them if you can.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch
Summary & Status

Key Questions about Increased Transparency in Generic Drug Approvals

A structured overview of the legislative process, official sources, status and civic context.

What is the official ID of this bill?

The official print number for this legislation is HR 3839.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2023-06-06.

What are the main provisions?

Key points include:

  • Generic drug manufacturers can request information on original drug composition to ensure their versions are identical.
  • If a generic differs from the original, the agency must disclose which ingredients and quantities are different.
  • The agency cannot reverse its decision on drug identity unless the original drug was withdrawn for safety reasons or an error was identified.
  • Clear guidelines on how the agency will assess generic drug identity are to be issued within one year.

What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Dunn, Neal P. [R-FL-2].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Health.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-25.

Analysis and Potential Impact of HR 3839

We don't know, that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge. Review our public AI processing logs for full transparency, and use Lustra to track active legislation for instant status push notifications.

CATEGORIES

Health